Short seller Scorpion Capital disclosed a short position in TransMedics Group Inc (NASDAQ:TMDX) accusing the organ transplant tech. company of fraudulent practices, including kickbacks, billing fraud, ...

TransMedics Group, Inc. TMDX recently issued a statement refuting the claims made in a report by short-seller Scorpion ...

TransMedics is facing allegations of fraud, organ trafficking, and unethical practices that have triggered shareholder ...

Group addressed what we believe are inaccurate and misleading claims made in a short-seller report issued by Scorpion ...

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Pomerantz LLP is investigating claims on behalf of investors of TransMedics Group, Inc. ("TransMedics" or the "Company") (NASDAQ:TMDX). Such ...

If you purchased TransMedics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a ...

Shares of organ transplant innovator TransMedics Group ( TMDX -1.41%) fell 15.7% through Thursday trading, according to data from S&P Global Market Intelligence. TransMedics was the target of an ...

Scorpion Capital accuses TransMedics of fraudulent practices, kickbacks, and racketeering, setting a price target of $0.00. TransMedics denies the claims, stating the allegations aim to manipulate ...

The big sell-off came after activist short seller Scorpion Capital released a scathing report about TransMedics. Scorpion stated in its report, "TransMedics is the most extreme and grotesque ...

Eli Lilly is reenergizing its attempt to challenge Novartis and Roche for a breast cancer market, kicking off the J.P. Morgan ...

Eli Lilly said it would acquire a cancer program from Scorpion Therapeutics in a deal worth up to $2.5 billion, as it ...